Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Mar. 31, 2017 |
Mar. 31, 2016 |
Jun. 30, 2016 |
Jun. 30, 2015 |
|
| Revenues | $ 37 | $ 379 | $ 247 | $ 673 | $ 948 | $ 1,851 |
| Operating expenses: | ||||||
| Research and development (related party of $225, $244, $670 and $723), net of grant income of ($44, $7, $84 and $7) | 1,136 | 1,048 | 3,005 | 2,303 | 3,156 | 3,495 |
| General and administrative (related party of $191, $303, $553 and $395) | 2,837 | 2,403 | 7,657 | 5,509 | 7,685 | 5,022 |
| Total operating expenses | 3,973 | 3,451 | 10,662 | 7,812 | 10,841 | 8,517 |
| Operating loss | (3,936) | (3,072) | (10,415) | (7,139) | (9,893) | (6,666) |
| Other income (expense): | ||||||
| Interest expense (related party of $481, $323, $1,447 and $323) | (481) | (323) | (1,447) | (323) | (807) | 0 |
| Interest income | 8 | 5 | 33 | 9 | 22 | 9 |
| Royalty income | 4 | 5 | 20 | 17 | 21 | 32 |
| Total other income (expense) | (469) | (313) | (1,394) | (297) | (764) | 41 |
| Consolidated net loss | (4,405) | (3,385) | (11,809) | (7,436) | (10,657) | (6,625) |
| Net loss attributable to noncontrolling interest | 492 | 349 | 1,606 | 349 | 893 | 0 |
| Net loss attributable to iBio, Inc. | (3,913) | (3,036) | (10,203) | (7,087) | (9,764) | (6,625) |
| Preferred stock dividends | (26) | 0 | (26) | 0 | ||
| Net loss available to iBio, Inc. | (3,939) | (3,036) | (10,229) | (7,087) | (9,764) | (6,625) |
| Comprehensive loss: | ||||||
| Consolidated net loss | (4,405) | (3,385) | (11,809) | (7,436) | (10,657) | (6,625) |
| Other comprehensive income (loss) - foreign currency translation adjustments | 0 | 2 | 0 | (6) | (4) | (25) |
| Comprehensive loss | $ (4,405) | $ (3,383) | $ (11,809) | $ (7,442) | $ (10,661) | $ (6,650) |
| Loss per common share attributable to iBio, Inc. stockholders - basic and diluted | $ (0.04) | $ (0.04) | $ (0.11) | $ (0.09) | $ (0.12) | $ (0.09) |
| Weighted-average common shares outstanding - basic and diluted | 89,109 | 81,158 | 89,109 | 78,587 | 80,973 | 71,495 |
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|